References
- Chen H S, Pellegrini J W, Aggarwal S K, Lei S Z, Warach S, Jensen F E, Lipton S A. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci 1992; 12: 4427–4436, [INFOTRIEVE], [CSA]
- Chen H S, Wang Y F, Rayudu P V, Edgecomb P, Neill J C, Segal M M, Lipton S A, Jensen F E. Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation. Neuroscience 1998; 86: 1121–1132, [INFOTRIEVE], [CROSSREF], [CSA]
- Cornblath D R, McArthur J C. Predominantly sensory neuropathy in patients with AIDS and AIDS-related complex. Neurology 1988; 38: 794–796, [INFOTRIEVE], [CSA]
- Jones G, Power C. Regulation of neural cell survival by HIV-1 infection. Neurobiol Dis 2006; 21: 1–17, [INFOTRIEVE], [CROSSREF], [CSA]
- Lipton S A. Memantine prevents HIV coat protein-induced neuronal injury in vitro. Neurology 1992; 42: 1403–1405, [INFOTRIEVE], [CSA]
- Maier C, Dertwinkel R, Mansourian N, Hosbach I, Schwenkreis P, Senne I, Skipka G, Zenz M, Tegenthoff M. Efficacy of the NMDA-receptor antagonist memantine in patients with chronic phantom limb pain—results of a randomized double-blinded, placebo-controlled trial. Pain 2003; 103: 277–283, [INFOTRIEVE], [CROSSREF], [CSA]
- Medvedev I O, Malyshkin A A, Belozertseva I V, Sukhotina I A, Sevostianova N Y, Aliev K, Zvartau E E, Parsons C G, Danysz W, Bespalov A Y. Effects of low-affinity NMDA receptor channel blockers in two rat models of chronic pain. Neuropharmacology 2004; 47: 175–183, [INFOTRIEVE], [CROSSREF], [CSA]
- Nath A, Haughey N J, Jones M, Anderson C, Bell J E, Geiger J D. Synergistic neurotoxicity by Human Immunodeficiency Virus proteins Tat and gp120: protection by memantine. Ann Neurol 2000; 47: 186–194, [INFOTRIEVE], [CROSSREF], [CSA]
- Parsons C G. NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol 2001; 429: 71–78, [INFOTRIEVE], [CROSSREF], [CSA]
- Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius H J, Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003; 348: 1333–1341, [INFOTRIEVE], [CROSSREF], [CSA]
- Sang C N, Booher S, Gilron I, Parada S, Max M B. Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials. Anesthesiology 2002; 96: 1053–1061, [INFOTRIEVE], [CROSSREF], [CSA]
- Schifitto G M, McDermott M PP, McArthur J CM, Marder K M, Sacktor N M, McClernon D RB, Conant K M, Cohen B M, Epstein L GM, Kieburtz K M, the NEAD Consortium. Markers of immune activation and viral load in HIV-associated sensory neuropathy. Neurology 2005; 64: 842–848, [INFOTRIEVE], [CSA]
- Tariot P N, Farlow M R, Grossberg G T, Graham S M, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291: 317–324, [INFOTRIEVE], [CROSSREF], [CSA]
- Toggas S M, Masliah E, Mucke L. Prevention of HIV-1 gp120-induced neuronal damage in the central nervous system of transgenic mice by the NMDA receptor antagonist memantine. Brain Res 1996; 706: 303–307, [INFOTRIEVE], [CROSSREF], [CSA]
- Tyor W R, Wesselingh S L, Griffin J W, McArthur J C, Griffin D E. Unifying hypothesis for the pathogenesis of HIV-associated dementia complex, vacuolar myelopathy, and sensory neuropathy. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 9: 379–388, [INFOTRIEVE], [CSA]